Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting respiratory conditions.

Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, and Lonza, one of the world’s largest contract development and manufacturing organizations ...

Ethris and Lonza agreed to collaborate on the development of room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates, designed for mucosal delivery to combat respiratory ...

Under the terms of the agreement, Lonza will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized ...

Formulations to be developed at Lonza’s Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US), in accordance with current Good Manufacturing Practice (cGMP) standards ...

AstraZeneca and its biologics research arm MedImmune have signed a five-year strategic research collaboration with Ethris, an mRNA-based therapeutics company specialising in pulmonary disease.

Samina Hamied, 48, third generation heir to Cipla, founded in 1935 by her grandfather Khwaja Abdul Hamied, challenges herself ...

Credit: mi_viri/Shutterstock. Ethris has partnered with contract development and manufacturing organisation Lonza for the development of room-temperature stable mRNA vaccine candidates targeting ...

German biotech Ethris, a company developing RNA therapeutics and vaccines, and Swiss contract development and manufacturing organization Lonza (SWX: LONN), have announced a collaboration. The deal is ...